- WuXi AppTec (WUXAY, Financial) reported a 21.0% year-over-year increase in Q1 2025 revenue, reaching RMB9.65 billion.
- Net profit attributable to owners rose 89.1% YoY to RMB3.67 billion, with adjusted non-IFRS net profit up 40.0% to RMB2.68 billion.
- Backlog for continuing operations increased by 47.1% YoY to RMB52.33 billion, signaling strong future revenue prospects.
WuXi AppTec (WUXAY), a global leader in R&D and manufacturing services for the pharmaceutical and life sciences industry, posted a robust first-quarter performance for 2025. The company's total revenue surged by 21.0% year-over-year, reaching RMB9.65 billion, driven by a 23.1% increase in revenue from continuing operations, which amounted to RMB9.39 billion.
The company experienced significant growth in profitability metrics, with net profit attributable to company owners soaring 89.1% year-over-year to RMB3.67 billion. Additionally, the adjusted non-IFRS net profit rose by 40.0% to RMB2.68 billion, highlighting the financial health and operational efficiency improvements within the organization.
WuXi AppTec's contract research, development, and manufacturing organization (CRDMO) platform played a pivotal role in this growth. The WuXi Chemistry segment recorded a 32.9% revenue increase year-over-year, while the TIDES segment saw an impressive 187.6% rise. As of March 31, 2025, the backlog for continuing operations jumped by 47.1% year-over-year, reaching RMB52.33 billion.
The company remains committed to maintaining its 2025 guidance with a projected 10-15% revenue growth from continuing operations. Operational cash flow also improved significantly, climbing 41.8% year-over-year to RMB3.03 billion, thanks to enhanced operational efficiencies and effective financial management practices.
WuXi AppTec continues its global expansion efforts, with recent FDA inspections completed successfully at its Changzhou and Taixing API manufacturing sites. The company aims to expand its small molecule API and solid phase peptide synthesizer capacities by the end of 2025, supporting future growth and innovation in drug development and manufacturing.
